---
title: "Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286462934.md"
description: "Maxim Group analyst Jason McCarthy has reiterated a Buy rating on Aprea (APRE) stock, maintaining a $5 price target. His positive outlook is based on the promising clinical profile of APR-1051, which has shown early anti-tumor activity and a favorable safety profile. Aprea's financial position is bolstered by a recent $30M equity raise, providing a solid cash runway for advancing its Phase 1 program. Additionally, Wedbush has also issued a Buy rating with a $6 price target for the stock."
datetime: "2026-05-14T20:15:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286462934.md)
  - [en](https://longbridge.com/en/news/286462934.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286462934.md)
---

# Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target

Maxim Group analyst Jason McCarthy has maintained their bullish stance on APRE stock, giving a Buy rating today.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Jason McCarthy has given his Buy rating due to a combination of factors, including the emerging clinical profile of APR-1051 and Aprea’s solid financial position. He highlights that APR-1051, a WEE1 inhibitor, has shown early signs of anti-tumor activity, including a confirmed partial response in uterine carcinosarcoma and additional evidence of disease control, while maintaining a favorable safety and tolerability profile that compares well versus competing agents.

He also notes that the company’s cash balance, recently strengthened by a $30M equity raise, provides sufficient runway to advance the Phase 1 program and generate further data, including at upcoming ASCO presentations. McCarthy’s model assumes eventual commercialization of APR-1051 in uterine serous carcinoma and platinum-resistant ovarian cancer, with an 80% risk adjustment applied, and he maintains a $5 price target, reflecting meaningful upside potential from current levels.

McCarthy covers the Healthcare sector, focusing on stocks such as Moleculin Biotech, Aprea Therapeutics, and Gain Therapeutics. According to TipRanks, McCarthy has an average return of \-14.2% and a 32.87% success rate on recommended stocks.

In another report released today, Wedbush also reiterated a Buy rating on the stock with a $6.00 price target.

### Related Stocks

- [APRE.US](https://longbridge.com/en/quote/APRE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)
- [GANX.US](https://longbridge.com/en/quote/GANX.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [HC Wainwright Analysts Increase Earnings Estimates for CTMX](https://longbridge.com/en/news/286258226.md)
- [These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results](https://longbridge.com/en/news/286301750.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)